News Article

Mallinckrodt Pharmaceuticals has agreed to sell Therakos, the world leader in extracorporeal photopheresis systems (ECP), kits and drugs to leading global private markets manager CVC for $925 million.

The Candesic team, led by Managing Partner Dr Leonid Shapiro and supervised by Principal Floris Wentholt and Engagement Manager Fabio Ruffinoni provided commercial due diligence to CVC.

Therakos’ work has broad applicability in the context of immunomodulation for a range of different indications, and there are significant opportunities to expand its indications, enter new geographies and bring its innovative treatment to more patients around the world.

Thanks to all who worked on the deal. We wish every success to Cathrin Petty, Managing Partner Head of Healthcare, Phil Robinson, Senior Managing Director (Healthcare), and Marta Kowalska, Investment Director (all CVC) with their latest acquisition, which we are certain will go on to even greater success under CVC’s stewardship.

Candesic offers a wide range of services including strategic consulting, commercial due diligence, digital consulting and tech-enabled strategic planning. To find out more, email [email protected].